Sunday 18 October 2026
Export COYA’s income statement to Excel — free account
Coya Therapeutics, Inc.
COYA Healthcare Biotechnology
Coya Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.9 million, up 123.6% from fiscal 2024. In the quarter to June 2026, revenue grew 49.0%, EPS grew 22.2% and free cash flow fell 27.8%, each against the same quarter a year earlier.
4.27
0.07
−1.61%
Follow COYA
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | 3 |
P/E ratio |
— | — | — | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | 7.72 | 9.59 | 6.40 |
P/S ratio |
— | — | — | 0.00 | 0.00 | 12.21 |
Altman Z″-Score (non-manufacturers) |
— | — | — | 9.07 | 9.09 | 5.24 |
P/FCF ratio |
— | — | — | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | — | — | (31.57) | (36.24) | (96.35) |
P/B ratio |
— | — | — | 1.99 | 2.21 | 2.26 |
Price to Tangible BV |
— | — | — | 1.99 | 2.21 | 2.26 |
EV/Sales |
— | — | — | 0.00 | 0.00 | 7.95 |
EV/EBITDA |
— | — | — | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | (4.57) | (6.02) | (5.88) |
EV/FCF |
— | — | — | (4.21) | (6.01) | (5.31) |
Quick Ratio |
19.51 | 3.78 | 1.55 | 7.94 | 10.02 | 7.97 |
Current Ratio |
19.57 | 3.99 | 1.88 | 8.15 | 11.59 | 8.50 |
Net Debt/EBITDA |
12.55 | 0.89 | (0.72) | 4.14 | 2.23 | 2.08 |
Debt/Assets |
0.00% | 0.00% | 154.43% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | (1.54) | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.24 | 0.08 | 0.17 |
Operating CF/Net income |
0.53 | 0.80 | 0.59 | 1.40 | 0.69 | 0.51 |
Capex/Depreciation |
— | (8.50) | (19.16) | (19.82) | (0.91) | (42.50) |
Interest Coverage |
(35.63) | — | — | — | — | — |
| 0.00% | 173.42% | 109.64% | (86.60%) | (39.57%) | (51.39%) | |
| 0.00% | (72.25%) | (185.70%) | (32.17%) | (34.76%) | (45.02%) | |
ROIC |
0.00% | 0.00% | 0.00% | (164.17%) | (871.34%) | 0.00% |
Return on Tangible Assets |
(8.83%) | (137.54%) | (354.44%) | (22.06%) | (36.72%) | (48.16%) |
Average Days of Receivables |
0.00 | — | — | 456.08 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 91.66% | 333.86% | 210.61% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 130.51% | 250.02% | 144.09% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 14.53% | 74.94% | 53.99% |
Graham Net Nets |
— | — | — | 0.50 | 0.45 | 0.44 |
Graham Number |
— | — | — | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | (11.21%) | (17.10%) | (21.90%) |
Free Cash Flow Yield |
— | — | — | (17.14%) | (11.81%) | (12.27%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.59 | 0.23 | 0.47 |
Operating CF per Share |
(0.04) | (1.51) | (2.79) | (1.10) | (0.68) | (0.64) |
Capex per Share |
0.00 | (0.05) | (0.20) | (0.05) | 0.00 | (0.07) |
Free Cash Flow per Share |
(0.04) | (1.56) | (3.00) | (1.15) | (0.68) | (0.71) |
Cash per Share |
0.90 | 1.68 | 2.29 | 3.21 | 2.52 | 2.80 |
Shareholders Equity per Share |
0.86 | 1.41 | (3.24) | 3.51 | 2.60 | 2.57 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.86 | 1.41 | (3.24) | 3.51 | 2.60 | 2.57 |
Free Cash Flow |
(0.39) | (4.04) | (7.76) | (11.73) | (10.31) | (11.90) |
Working Capital |
8.30 | 3.44 | 3.36 | 36.14 | 40.48 | 44.07 |
Capital Expenditures |
— | (0.14) | (0.52) | (0.54) | (0.02) | (1.16) |
Net Current Asset Value |
8.30 | 3.44 | (9.60) | 35.57 | 39.54 | 43.02 |
EV/EBIT |
— | — | — | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.00 | 0.00 | 0.09 | 0.01 | 0.15 |
Price to Operating Income |
— | — | — | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||
Depreciation/Fixed assets |
— | 0.13 | 0.29 | 0.42 | 0.71 | 2.45 |
Cash ROIC |
(2.30%) | (50.60%) | (73.91%) | (17.19%) | (13.24%) | (13.25%) |
Accounts Receivable Turnover |
— | — | — | 1.60 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | — | — | 3.75 | — | — |
Average Payables |
— | 0.65 | 1.34 | 1.49 | 1.37 | 1.32 |
Average Assets |
— | 6.77 | 6.59 | 24.83 | 42.80 | 47.15 |
Average Common Equity |
— | (2.82) | (11.17) | 9.22 | 37.61 | 41.30 |
Columns are period end dates